PIK3CA mutation and histological type in breast carcinoma: High frequency of mutations in lobular carcinoma

Journal of Pathology

Volumn 208, Issue 3, 2006, Pages 350-355

  Buttitta, Fiamma ^a   Felicioni, Lara ^a   Barassi, Fabio ^a   Martella, Carla ^a   Paolizzi, Diego ^a   Fresu, Giuseppina ^a   Salvatore, Simona ^a   Cuccurullo, Franco ^a   Mezzetti, Andrea ^a   Campani, Daniela ^b   Marchetti, Antonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Breast cancer histology; Lobular carcinoma; PIK3CA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN PIK3CA; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR VOLUME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LOGISTIC MODELS; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTOR, ERBB-2;

EID: 32244445352     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1908     Document Type: Article

References (42)

1. Keith CT, Schreiber SL. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 1995;270:50-51.
2. Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999;402:313-320.
3. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253:239-254.
4. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997;275:665-668.
5. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev Cancer 2002;2:489-501.
6. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004;170:1088-1094.
7. Byun DS, Cho K, Ryu BK, Lee MG, Park JI, Chae KS, et al. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer 2003;104:318-327.
8. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002;62:3636-3640.
9. Woenckhaus J, Steger K, Werner E, Fenic I, Gamerdinger U, Dreyer T, et al. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 2002;198:335-342.
10. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-7429.
11. Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 1997;276:1848-1850.
12. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005;102:802-807.
13. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet 1999;21:99-102.
14. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19:2739-2744.
15. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114:242-248.
16. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
17. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-1224.
18. Hawthorne VS, Yu D. PI3K: missense mutation motivates malignancy. Cancer Biol Ther 2004;3:776-777.
19. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004;64:5048-5050.
20. Wang Y, Helland A, Holm R, Kristensen GB, Borrese-Dale AL. PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005;25:322.
21. Li VS, Wong CW, Chan TL, Chan AS, Zhao W, Chu KM, et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005;5:29.
22. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-2878.
23. Saal LH, Holm K, Maurer M, Maurer M, Memeo L, Su T, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-2559.
24. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-775.
25. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-1480.
26. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-7681.
27. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, et al. Invasive breast carcinoma. In Pathology and Genetics of the Breast and Female Genital Organs, Tavassoli FA, Devilee P (eds). IARC Press: Lyon, 2003; 13-59.
28. Frierson HF Jr, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995;103:195-198.
29. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976;3:2303-2308.
30. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-865.
31. Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993;53:4665-4669.
32. Eichhorn JH. Medullary carcinoma, provocative now as then. Semin Diagn Pathol 2004;21:65-73.
33. Komenaka IK, El-Tamer MB, Troxel A, Hamel-Bena D, Joseph KA, Horowitz E, et al. Pure mucinous carcinoma of the breast. Am J Surg 2004;187:528-532.
34. Rosai J. Surgical Pathology. Mosby: Edinburgh, 2004.
35. Rosen PP. The pathology of invasive breast carcinoma. In Breast Disease, Harris JR, Hellman S, Henderson IC, Kinne DW (eds). JB Lippincot: Philadelphia, PA, 1991; 245-325.
36. Kruger S, Fahrenkrog T, Muller H. Proliferative and apoptotic activity in lobular breast carcinoma. J Mol Med 1999;4:171-174.
37. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149-R156.
38. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
39. Lei H, Sjoberg-Margolin S, Salahshor S, Werelius B, Jandakova E, Hemminki K, et al. CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer 2002;98:199-204.
40. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001;92:404-408.
41. Berx G, Cleton-Jansen AM, Nollet F, De Leeuw WJ, Van de Vijer M, Cornelisse C, et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995;14:6107-6115.
42. Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 1979;3:467-488.